Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Item

http://www.wikidata.org/entity/Q33558161

Q33558161

about

Current Trends of Renal Impairment in Multiple Myeloma Treatment of relapsed and refractory multiple myeloma European perspective on multiple myeloma treatment strategies in 2014 Are maintenance and continuous therapies indicated for every patient with multiple myeloma?Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.How we manage autologous stem cell transplantation for patients with multiple myeloma Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials Therapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis Posttransplant maintenance therapy in multiple myeloma: the changing landscape.The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.Advances in multiple myeloma therapy during two past decades.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Current Review on High-Risk Multiple Myeloma.Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.Bortezomib for the treatment of multiple myeloma.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.

P2860

Q26740444-A8AFF678-3C4A-47DE-B165-633ABF25177C Q26749180-1965295A-21EB-4B18-B003-83A56BEABC31 Q27005966-2F352A59-A810-450C-9EEF-1BFA081E6A67 Q30249790-76EE380B-4B24-4B8D-8820-7116B1CD1DD0 Q33418712-4AD4B66F-3E49-46A3-90A0-27BD8D681908 Q34019581-0001E8AD-C2AE-4598-A7D3-64551022D14A Q35603608-7D581F2F-E2A3-42A3-B0A1-96E903CC4561 Q35760754-95846451-A08A-44F7-9125-77194B0A201D Q36088601-6E1117DF-C8CC-496B-8971-9BB07DD508CD Q36115636-8100903E-EFB6-49C7-89AE-BF5432995F36 Q36196981-91663ECD-4101-4AA6-A9E8-83629849A4C2 Q36708969-96E1C697-1C84-481D-970D-D622837878DE Q37375516-D8D4CE7E-F484-4093-952E-B7E2DC22989F Q37737800-BA7CCA0D-A496-4DE9-BD8D-C9B019873F6A Q38231358-D03CE9DD-E3CF-4963-BD37-D04FC26EF114 Q38248293-278EBD4F-4753-4C7D-B207-1998C1E9B5E7 Q38261677-4A200777-CEF0-47A9-A25C-3E4A128C2D25 Q38555091-9C72EE4F-98C0-40EF-9C7D-29104582317E Q38650700-84AC3B3B-A8CB-4D33-B182-F574E163258D Q38874675-3FD1FF6B-2470-426B-9030-C5CD35848A0D Q38895167-C8BCEEAF-6E07-4DAD-A663-124E04BA71BD Q38900024-D943ED83-A9D7-4206-A4FE-95317B43037D Q38959138-D63A35EB-76BE-426C-906A-C6B382165F61 Q39273146-4D527FEC-1314-4F0F-89FA-A2D2EE9A9011 Q42551347-1688396F-53E4-4A1F-B02F-8C8BBF7DBABC Q42573839-C5BC7A81-4259-4025-A492-DC8FCB376648 Q47162496-A6646665-F751-473A-BDF0-57F03F264513 Q47604607-48FAC7C0-EA21-48E9-9746-31AB23AF824C Q47794767-0E2CAE16-6D43-48D0-B418-B4079DC9AF3B Q50934141-DF0DD10C-485D-4803-8386-E25104FCB869 Q53656759-EB2F3E47-C5C6-4DA4-8DDB-686B0BC250F8

P2860

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Item

http://www.wikidata.org/entity/Q33558161

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu